2012
DOI: 10.1111/j.1469-0691.2012.03880.x
|View full text |Cite
|
Sign up to set email alerts
|

EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)

Abstract: The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has revised the EDef 7.1 document on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for fermentative yeasts. Changes are: dimethylsulphoxide is now the recommended solvent for caspofungin, micafungin and fluconazole; the shelf-life of plates containing the echinocandins prepared from stock solutions in dimethylsulphoxide is ext… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
447
2
5

Year Published

2015
2015
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 472 publications
(455 citation statements)
references
References 8 publications
1
447
2
5
Order By: Relevance
“…With rapidly expanded usage of echinocandins, the first-line therapy for invasive candidiasis, an alarming trend of rising echinocandin resistance in C. glabrata has posed a serious clinical challenge (4)(5)(6). Detection of echinocandin resistance can be assessed phenotypically, using either microdilution or disc diffusion MIC assays performed in accordance with guidance of the Clinical and Laboratory Standards Institute (CLSI) M27-A3 standard (7) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Definitive Document Edef 7.2 (8). Current echinocandin clinical breakpoints for C. glabrata were established by the CLSI for all echinocandins and by EUCAST for micafungin and anidulafungin.…”
mentioning
confidence: 99%
“…With rapidly expanded usage of echinocandins, the first-line therapy for invasive candidiasis, an alarming trend of rising echinocandin resistance in C. glabrata has posed a serious clinical challenge (4)(5)(6). Detection of echinocandin resistance can be assessed phenotypically, using either microdilution or disc diffusion MIC assays performed in accordance with guidance of the Clinical and Laboratory Standards Institute (CLSI) M27-A3 standard (7) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Definitive Document Edef 7.2 (8). Current echinocandin clinical breakpoints for C. glabrata were established by the CLSI for all echinocandins and by EUCAST for micafungin and anidulafungin.…”
mentioning
confidence: 99%
“…The American Type Culture Collection (ATCC) strains Candida albicans ATCC 90028, Candida parapsilosis ATCC 22019, and Candida krusei ATCC 6258 served as quality controls, as recommended in the EUCAST definitive document (22). SQ preparations were established according to the manufacturer's instructions: yeast colonies harvested from Sabouraud's dextrose agar (BD) were suspended in physiological saline solution (0.5 McFarland standard) (Merck KgaA, Darmstadt, Germany).…”
Section: Methodsmentioning
confidence: 99%
“…Harmonized CLSI and EUCAST methods of susceptibility testing [68][69][70][71][72][73][74][75] defined the Amphothericin B susceptible-and resistant breakpoints according to EUCAST definition as <1 mg/l and >1 mg/l, respectively for C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei [76] whereas the susceptible-and resistant breakpoints for A. fumigatus and A. niger are <1 mg/l and >2 mg/L, respectively for other Aspergillus species evidence allowing breakpoint definitions is insufficient [77]. In the following only those studies are reviewed which have adopted these standards for the quantitation of minimal inhibitory concentrations (MICs).…”
Section: Longitudinal Surveillance Studies Indicating the Existence Omentioning
confidence: 99%